Ligand Pharmaceuticals Incorporated

LGND · Healthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide

Ligand Pharmaceuticals Incorporated (LGND), in the Healthcare sector, has 27 disclosed filings on Paydirt over the trailing twelve months from 1 member of Congress and 9 corporate insiders: 3 purchases and 24 sales, 1 filed past the deadline. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Sep 10 and filed Sep 14. The most active filer was Andrew Reardon with 9 filings.

Add to watchlist

Filings, ttm

3 buys · 24 sells · 1 late

Traders, ttm

1 congress · 9 insiders

Volume, ttmiDollar value disclosed in the window

$31.4M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

Sep 10

Filed Sep 14

ADViAverage daily dollar volume

$104.4M

market data

Share price · 12M

$283 (+66.0%)

Adjusted for splits and dividends.

Volume by month

Buys $1.1M Sells $34.4M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed

Andrew Reardon CLO & Secretary 9 filings OE

Octavio Espinoza Chief Financial Officer 7 filings JL

John L Lamattina Director 4 filings GC

Gilbert Cisneros Representative 3 filings SS

Stephen L Sabba Director 3 filings JA

Jason Aryeh Director 2 filings JH

Jason Haas Director 2 filings JK

John W Kozarich Director 2 filings

Recent filings

Martine ZimmermannSALE Director $342K
1,200 sh × $285.00
Exec Sep 10
Filed Sep 14 · 4:59 PM ET Andrew ReardonSALE CLO & Secretary $1.3M
4,700 sh across 4 lots
Exec Sep 3
Filed Sep 8 · 6:34 PM ET Octavio EspinozaSALE Chief Financial Officer $9.2M
31,641 sh × $292.06
Exec Aug 12
Filed Aug 14 · 5:05 PM ET Jason HaasSALE Director $2.1M
7,138 sh × $292.81
Exec Aug 12
Filed Aug 14 · 5:04 PM ET Andrew ReardonSALE CLO & Secretary $1.3M
4,505 sh across 6 lots
Exec Aug 3
Filed Aug 4 · 6:42 PM ET Andrew ReardonSALE CLO & Secretary $1.5M
4,796 sh across 6 lots
Exec Jul 1
Filed Jul 6 · 5:11 PM ET Stephen L SabbaSALE Director $545K
2,145 sh × $254.00
Exec Jun 16
Filed Jun 18 · 5:30 PM ET Jason HaasSALE Director $1.7M
6,461 sh across 2 lots
Exec Jun 12
Filed Jun 15 · 5:30 PM ET John L LamattinaSALE Director $1.0M
4,102 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET Jason AryehSALE Director $1.2M
5,000 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET Gilbert CisnerosPURCHASE Representative $8K
$1K–15K bracket
Exec May 29
Filed Jun 8 Andrew ReardonSALE CLO & Secretary $999K
4,400 sh across 5 lots
Exec Jun 1
Filed Jun 2 · 5:30 PM ET John W KozarichSALE Director $455K
2,034 sh across 2 lots
Exec May 12
Filed May 14 · 5:30 PM ET Andrew ReardonSALE CLO & Secretary $1.0M
4,532 sh across 5 lots
Exec May 1
Filed May 4 · 5:30 PM ET Gilbert CisnerosPURCHASE Representative $8K
$1K–15K bracket
Exec Mar 3
Filed Apr 7 Andrew ReardonSALE CLO & Secretary $846K
4,203 sh across 4 lots
Exec Apr 1
Filed Apr 2 · 5:30 PM ET John L LamattinaSALE Director $434K
2,161 sh × $200.76
Exec Mar 6
Filed Mar 31 · 5:30 PM ET † Stephen L SabbaSALE Director $208K
1,000 sh × $207.87
Exec Mar 23
Filed Mar 25 · 5:30 PM ET Octavio EspinozaSALE Chief Financial Officer $688K
3,057 sh × $225.00
Exec Mar 11
Filed Mar 13 · 5:30 PM ET Octavio EspinozaSALE Chief Financial Officer $2.8M
13,370 sh across 10 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET Andrew ReardonSALE CLO & Secretary $666K
3,200 sh across 3 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET Stephen L SabbaSALE Director $410K
2,034 sh × $201.50
Exec Mar 3
Filed Mar 5 · 5:30 PM ET Gilbert CisnerosPURCHASE Representative $16K
2 lots · $2K–30K bracket
Exec Jan 5
Filed Feb 13 Octavio EspinozaSALE Chief Financial Officer $340K
1,804 sh × $188.31
Exec Dec 12 2025
Filed Dec 16 2025 · 5:30 PM ET John L LamattinaSALE Director $859K
4,179 sh across 2 lots
Exec Nov 7 2025
Filed Nov 12 2025 · 5:30 PM ET